Lite Strategy (LITS) Operating Income (2010 - 2026)
Lite Strategy (LITS) posted quarterly Operating Income of -$21.6 million for Q1 2026, down 679.02% year-over-year from $3.7 million in Q1 2025, and up 27.65% quarter-over-quarter from -$29.9 million in Q4 2025.
Lite Strategy (LITS) Operating Income (2010 - 2026) Analysis & Trends
Lite Strategy's Operating Income history runs 17 years deep, the most recent figure standing at -$21.6 million for Q1 2026.
- In Q1 2026, Operating Income fell 679.02% year-over-year to -$21.6 million; the TTM figure through Mar 2026 stood at -$58.1 million (down 73.12% YoY), while the FY2025 annual figure was -$17.5 million, down 220.03% from the prior year.
- Operating Income for Q1 2026 stood at -$21.6 million, up from -$29.9 million in the prior quarter.
- The five-year high for Operating Income was $55.3 million in Q3 2023, with the low at -$29.9 million in Q4 2025.
- The 5-year median for Operating Income is -$11.1 million (2023), against an average of -$7.8 million.
- The sharpest annual moves came in 2023 and 2025: Operating Income jumped 403.42% in 2023, then plunged 765.46% in 2025.
- Lite Strategy's Operating Income stood at $8.9 million in 2022, then plunged by 233.65% to -$11.9 million in 2023, then surged by 71.07% to -$3.5 million in 2024, then slumped by 765.46% to -$29.9 million in 2025, then grew by 27.65% to -$21.6 million in 2026.
- Business Quant data shows LITS's Operating Income at -$21.6 million in Q1 2026, -$29.9 million in Q4 2025, and -$3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.75 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.09 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 59.14 Bn | 54.00 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 133.12 Mn |
| 10 | Lite Strategy | 36.07 Mn | 28.52 Mn | - | -21.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.61 Mn |
| Dec 31, 2025 | -29.87 Mn |
| Sep 30, 2025 | -3.74 Mn |
| Jun 30, 2025 | -2.88 Mn |
| Mar 31, 2025 | -2.77 Mn |
| Dec 31, 2024 | -3.45 Mn |
| Sep 30, 2024 | -8.35 Mn |
| Jun 30, 2024 | -18.98 Mn |
| Mar 31, 2024 | -9.83 Mn |
| Dec 31, 2023 | -11.93 Mn |
| Sep 30, 2023 | 55.28 Mn |
| Jun 30, 2023 | -11.08 Mn |
| Mar 31, 2023 | -16.39 Mn |
| Dec 31, 2022 | 8.93 Mn |
| Sep 30, 2022 | -18.22 Mn |
| Jun 30, 2022 | -16.20 Mn |
| Mar 31, 2022 | -21.56 Mn |
| Dec 31, 2021 | -17.63 Mn |
| Sep 30, 2021 | -20.11 Mn |
| Jun 30, 2021 | -15.47 Mn |